



NEWS RELEASE

# ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

2025-01-06

LOS ANGELES--(BUSINESS WIRE)-- **ChromaDex Corp.** (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announced that it will participate in a webcasted company presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.

The company presentation will take place at 12:00 p.m. ET on Monday, January 13, 2025. The webcast can be accessed directly at <https://lythampartners.com/health2025/cdxc> or by visiting the conference home page at <https://lythampartners.com/health2025/>. A replay of the presentation will also be available through the same links.

1x1 investor meetings will be available after the event upon request by contacting your Lytham representative at [1x1@lythampartners.com](mailto:1x1@lythampartners.com) or ChromaDex's investor relations contact, Ben Shamsian, Vice President at Lytham Partners, at [shamsian@lythampartners.com](mailto:shamsian@lythampartners.com) or 646-829-9701.

For additional information on ChromaDex, visit [www.chromadex.com](http://www.chromadex.com).

## About ChromaDex:

**ChromaDex Corp.** (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the



full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality.

Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.

Niagen® is the active ingredient in ChromaDex's consumer products, sold as the brand Tru Niagen® , the number one healthy-aging NAD+ supplement in the United States† . Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at [www.truniagen.com](http://www.truniagen.com) ). ChromaDex supplies pharmaceutical-grade Niagen® to U.S. FDA-registered 503B outsourcing facilities, which compound and distribute intravenous and injectable Niagen® for clinics. These pharmaceutical-grade Niagen® products, known as Niagen IV and Niagen injections, are available exclusively at clinics with a prescription ([www.niagenplus.com](http://www.niagenplus.com)).

ChromaDex's robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at [www.chromadex.com](http://www.chromadex.com), where copies of press releases, news, and financial information are regularly published.

† Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

### ChromaDex Media Contact:

Kendall Knysch, Senior Director of Media Relations & Partnerships

310-388-6706 ext. 689

[kendall.knysch@chromadex.com](mailto:kendall.knysch@chromadex.com)

### ChromaDex Investor Relations Contact:

Ben Shamsian

Lytham Partners

646-829-9701

[shamsian@lythampartners.com](mailto:shamsian@lythampartners.com)

Source: ChromaDex Corporation